Literature DB >> 9629468

Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity.

R B Greenwald1, A Pendri, C D Conover, C Lee, Y H Choe, C Gilbert, A Martinez, J Xia, D Wu, M Hsue.   

Abstract

An improved synthesis of the hindered PEG-camptothecin diester transport form has been achieved using the Mukaiyama reagent. We have also assessed the effect of changing the electronic configuration of the (d-position of PEG-camptothecin transport forms on the rates of hydrolysis of the pro-moiety, and attempted to correlate these differences to efficacy in two animal models. In addition to the simple substitution of N for O, other synthetic modifications of these atoms were accomplished by employing heterobifunctional linker groups. The half lives by disappearance (rates of hydrolysis) of the transport forms in buffer and rat plasma were determined. It was established that anchimeric assistance to hydrolytic breakdown of the pro-moiety occurs in a predictable manner for some of these compounds. Results for the new derivatives in a P388 murine leukemic model and HT-29 human colorectal xenograft study are also presented. The use of a glycine linker group was found to provide similar efficacy in rodent models to that of simple camptothecin 20-PEG ester, and displayed enhanced pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9629468     DOI: 10.1016/s0968-0896(98)00005-4

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  14 in total

1.  Alkyne- and 1,6-elimination- succinimidyl carbonate - terminated heterobifunctional poly(ethylene glycol) for reversible "Click" PEGylation.

Authors:  Yumei Xie; Shaofeng Duan; M Laird Forrest
Journal:  Drug Discov Ther       Date:  2010

2.  Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins.

Authors:  Lin Song; Robert Bevins; Bradley D Anderson
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

3.  CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development.

Authors:  Cissy Young; Thomas Schluep; Jungyeon Hwang; Scott Eliasof
Journal:  Curr Bioact Compd       Date:  2011-03

4.  PAMAM-camptothecin conjugate inhibits proliferation and induces nuclear fragmentation in colorectal carcinoma cells.

Authors:  Giridhar Thiagarajan; Abhijit Ray; Alexander Malugin; Hamidreza Ghandehari
Journal:  Pharm Res       Date:  2010-06-15       Impact factor: 4.200

5.  Synthesis of a macromolecular camptothecin conjugate with dual phase drug release.

Authors:  A V Yurkovetskiy; A Hiller; S Syed; M Yin; X M Lu; A J Fischman; M I Papisov
Journal:  Mol Pharm       Date:  2004 Sep-Oct       Impact factor: 4.939

Review 6.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

7.  Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugates.

Authors:  Rong Tong; Jianjun Cheng
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

8.  Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.

Authors:  Ferro Nguyen; Peng Guan; David T Guerrero; Ivan S Alferiev; Michael Chorny; Garrett M Brodeur; Venkatadri Kolla; Koumudi Naraparaju; Lauren M Perry; Danielle Soberman; Benjamin B Pressly
Journal:  Cancer Res       Date:  2020-08-24       Impact factor: 12.701

9.  Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates.

Authors:  Megan E Fox; Steve Guillaudeu; Jean M J Fréchet; Katherine Jerger; Nichole Macaraeg; Francis C Szoka
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

10.  Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.

Authors:  Jeremy D Heidel; Thomas Schluep
Journal:  J Drug Deliv       Date:  2012-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.